ArticleTrials2016

Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial.

Nuno Sousa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.